Loading asset research
Atrium Therapeutics Inc. Common Stock
RNANasdaq · USD · StocksQuote as of · Exchange session not verified$10.36
+0.10%
Today
RNA
Loading 1D prices…
Market cap
$177.2M
Volume
247.4K
52w high
$16.7752w low
$10.00Company profile
Atrium Therapeutics Inc. Common Stock
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. It has a research collaboration and license agreement with Bristol-Myers Squibb Company and Eli Lilly and Company. The company was incorporated in 2025 and is headquartered in San Diego, California.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
San Diego, CA, United States
Fiscal year end
1231
CIK
2093101
Session & valuation
Open$10.37
Previous close$10.35
Day high$10.41
Day low$10.00
30-day avg. volume232.9K
Outstanding shares17.1M
Diluted EPS-$2.89
Latest annual period
P/E (trailing)-3.58
P/E (forward)-1.29
Price / book0.83
Beta—
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2834
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| NBPNovaBridge Biosciences American Depositary Shares | $183.9M | $0.00 | — | -$0.21 | -5.33% | Buy |
| ORGOOrganogenesis Holdings Inc. Class A Common Stock | $191.7M | $564.2M | +6.56% | $0.15 | -2.94% | Hold |
| ORMPOramed Pharmaceuticals Inc. Common Stock | $193.8M | $2M | +3.77% | $1.50 | -2.10% | Hold |
| NERVMinerva Neurosciences Inc Common Stock | $198.2M | $0.00 | — | -$34.67 | -0.24% | Hold |
| CRBPCorbus Pharmaceuticals Holdings Inc. Common Stock | $157.1M | $0.00 | — | -$5.90 | -1.33% | Buy |